



Press Release

Wednesday, August 8, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

**STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR
OXALIPLATIN INJECTION**

*Product to be launched through Pfizer
Amongst the first wave of generic approvals*

August 8, 2012: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received final ANDA approval for ***Oxaliplatin injection 50mg/10mL and 100mg/20mL***

The Company had in November 2011 received tentative approval from USFDA based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.

According to IMS data, the US market for generic Oxaliplatin is approximately USD 1.5 Billion.


Oxaliplatin is part of the Oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.

About Oxaliplatin

Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencyclins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest sterile capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Kannan N : +91 98450 54745 (Investors)	Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in

